Intellect Neurosciences, Inc. Issues Letter to Shareholders - GlobeNewswire press release

Shire is developing OX1 as a treatment for Friedreich’s Ataxia and possibly other diseases for which OX1 may qualify for orphan drug designation.

Via Friedreich Ataxia Scientific News